Major Shareholder Lynx1 Capital Increases Stake to 21% Post-Merger Announcement
PASG sits 38% above its 52-week low of $3.29 on light trading volume (0.4× avg).
Summary
Lynx1 Capital Management LP and Weston Nichols have increased their beneficial ownership in Passage Bio to 21% through a recent purchase, following the company's reverse merger announcement with Remix Therapeutics.
Key Events · Ownership and Investor Activity · PASG
-
Increased Ownership
Lynx1 Capital Management LP and Weston Nichols now beneficially own 21.0% of Passage Bio's common stock, up from a previous undisclosed stake below 20%.
-
Recent Share Purchase
On June 25, 2026, the reporting persons purchased 50,055 shares at an average price of $4.1175, totaling $206,101, immediately following the reverse merger announcement.
-
Shift to 13D Filing
The increase in ownership above 20% triggered a change from a Schedule 13G to a Schedule 13D filing, indicating a more active investment stance.
-
Commitment to Merger Financing
The reporting persons have agreed to participate in the Concurrent Financing related to Passage Bio's definitive reverse merger agreement with Remix Therapeutics.
Analysis · PASG · Life Sciences
This filing reveals a significant increase in ownership by Lynx1 Capital Management LP and Weston Nichols to 21% of Passage Bio's common stock. The recent purchase of over $200,000 in shares occurred immediately after the announcement of the reverse merger with Remix Therapeutics, signaling strong conviction in the combined entity's future. The shift from a passive 13G filing to an active 13D filing, coupled with their commitment to participate in the Concurrent Financing related to the merger, suggests this investor intends to take a more engaged role and sees substantial value in the post-merger company. This provides a vote of confidence amidst a period of significant corporate restructuring and a going concern warning.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 38.5% of the 1020 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $4.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.